Startups
iX Biopharma is a listed, specialty pharmaceutical and nutraceutical company focusing on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.
iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world’s first freeze-dried sublingual medicinal cannabis wafer.
The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products.
Subsidiaries:
iX Syrinx ( https://www.ixsyrinx.com )
Entity health ( https://www.entity-health.com )
iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world’s first freeze-dried sublingual medicinal cannabis wafer.
The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products.
Subsidiaries:
iX Syrinx ( https://www.ixsyrinx.com )
Entity health ( https://www.entity-health.com )
Overview
Location
Singapore
Employees
51-200
Founded date
2008
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 25, 2021 | iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products | iX Biopharma will receive an initial US$9 million upfront payment Eligible for up to US$239 million in development and sales milestone payments Double digit royalties on future product sales of any licensed product SINGAPORE, Nov. 25, 2021 ... |
| Nov 24, 2021 | Seelos Therapeutics : Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine - Form 8-K | Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine - New SLS-003 Program Extends Seelos' Ketamine Franchise into Additional Indications Inclu... |
Reviews 0
FAQ about iX Biopharma
When was iX Biopharma founded?
iX Biopharma was founded in 2008.
What has the press written about iX Biopharma?
Parsers VC has collected 3 articles mentioning iX Biopharma, among them “iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products” (Nov 25, 2021) and “Seelos Therapeutics : Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine - For...” (Nov 24, 2021).
Is iX Biopharma still active?
Yes, iX Biopharma is active; its latest activity on Parsers VC dates from Nov 29, 2021.